In this multicentre , open-label , randomised phase II trial , women with HER@-negative LR/MBC were randomly assigned in a @:@ ratio to paclitaxel ( @ mg/m@ intravenously -LSB- IV -RSB- on days @ , @ , and @ ) and bevacizumab ( @ mg/kg IV on days @ and @ ) every @ weeks for six cycles , followed by bevacizumab ( @ mg/kg IV on day @ ) every @ weeks ( AT ) or to paclitaxel ( @ mg/m@ IV on days @ and @ ) , bevacizumab ( @ mg/kg IV on day @ ) and capecitabine ( @ mg/m@ orally twice daily on days @ ) every @ weeks for eight cycles , followed by bevacizumab and capecitabine at the same doses every @ weeks ( ATX ) .